PubMed

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.PMID: 12693883 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

Ann Intern Med. 2003 Nov 18;139(10):810-6.PMID: 14623618 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B; Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group.

JAMA. 2001 Nov 28;286(20):2560-7.PMID: 11722270 [PubMed - indexed for MEDLINE]Related articlesFree article

When to start antiretroviral therapy in resource-limited settings.

Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators.

Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.PMID: 19620143 [PubMed - indexed for MEDLINE]Related articles

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.PMID: 11722271 [PubMed - indexed for MEDLINE]Related articlesFree article

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.PMID: 16323104 [PubMed - indexed for MEDLINE]Related articles

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.PMID: 10605973 [PubMed - indexed for MEDLINE]Related articlesFree article

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.PMID: 14640384 [PubMed - indexed for MEDLINE]Related articles

HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.

Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, Lange JM, Phanuphak P, Cooper DA.

AIDS. 2005 Jan 28;19(2):169-78.PMID: 15668542 [PubMed - indexed for MEDLINE]Related articles

CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.

Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson M, Delpech V, Phillips A, Sabin C; UK CHIC Study.

HIV Med. 2007 Apr;8(3):135-41.PMID: 17461856 [PubMed - indexed for MEDLINE]Related articles

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN.

AIDS. 2003 Sep 5;17(13):1907-15.PMID: 12960823 [PubMed - indexed for MEDLINE]Related articles

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA.

Ann Intern Med. 2000 Oct 3;133(7):493-503.PMID: 11015162 [PubMed - indexed for MEDLINE]Related articlesFree article

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.

Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar RL, Sahner DK, Duliege AM, Capra WB, Leong WP, Giedlin MA, Lane HC, Kahn JO.

JAMA. 2000 Jul 12;284(2):183-9.PMID: 10889591 [PubMed - indexed for MEDLINE]Related articlesFree article

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.PMID: 15319852 [PubMed - indexed for MEDLINE]Related articles

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.

Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD.

Ann Intern Med. 1999 Apr 6;130(7):570-7.PMID: 10189326 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration.

Lancet. 2004 Jul 3-9;364(9428):51-62.PMID: 15234856 [PubMed - indexed for MEDLINE]Related articles

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)]

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish. PMID: 17261244 [PubMed - indexed for MEDLINE]Related articlesFree article

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.PMID: 18765698 [PubMed - indexed for MEDLINE]Related articlesFree article

CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.

Zambarakji HJ, Newson RB, Mitchell SM.

Br J Ophthalmol. 2001 Jul;85(7):837-41.PMID: 11423459 [PubMed - indexed for MEDLINE]Related articlesFree article

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

AIDS. 2003 Mar 28;17(5):711-20.PMID: 12646794 [PubMed - indexed for MEDLINE]Related articles